TLR3 and melanoma: The TLR3 agonist, Poly(I:C), and the TLR9 agonist, CpG ODN 1826 [CpG], upon intra-tumoral administration, combined with the systematic metastasis of specific gp10025-33-activated pmel-1 T cells, enhanced IFN-γ production and the immunogenicity of B16F10 melanoma cell lines and improved the survival rate and eradication of subcutaneous 9-day B16F10 melanoma in some mice [72].